Skip to main content

Table 1 Characteristics of the studied drugs

From: Adoption of new drugs by physicians: a survival analysis

Drug Launching Degree of therapeutic Innovation* Approved indications Cost/DDD Alternatives (cost/DDD)
Cefditoren Sep-04 No therapeutic innovation Pneumonia, exacerbation of chronic bronchitis, pharyngitis, tonsillitis, skin infections €4.47 -6.26 Amoxicillin-clavulanate (€0.68) Cefuroxime axetil (€2.27)
Duloxetine Dec-05 No therapeutic innovation Neuropathic pain, depresión, generalised anxiety disorder (from jul-08) €1.99 Amitriptyline (€0.11)
Fluoxetine (€0.24)
Paroxetine (€0.79)
Etoricoxib Jul-04 No therapeutic innovation Osteoarthritis, rheumatoid artritis, acute gouty artritis, ankylosing spondylitis (from sep-08) €1.74 Ibuprofen (€0.24)
Diclofenac (€0.17)
Naproxen (€0.38)
Ezetimibe Mar-04 Insufficient evidence Primary hypercholesterolaemia, homozygous familial hypercholesterolaemia, homozygous sitosterolaemia €1.91  
Levocetirizine Apr-03 No therapeutic innovation Allergic rhinitis, chronic idiopathic urticaria €0.56 Cetirizine (€0.29)
Olmesartan May-04 No therapeutic innovation Hypertension €0.92 Losartan (€0.92) Enalapril (€0.13)
Pregabalin Jan-05 No therapeutic innovation Neuropathic pain, epilepsy, generalised anxiety disorder (from mar-06) €2.57 Gabapentin (€0.19)
Amitriptyline (€0.11)
Tiotropium Jan-03 Modest therapeutic innovation Chronic obstructive pulmonary disease €1.91 Ipratropium (€0.28)
  1. *No therapeutic innovation: The new drug has no added value over other drugs which are already available in the market for the same indication. Modest therapeutic innovation: The new drug provides more posology comfort. Insufficient evidence: Available evidence is insufficient or inconclusive, or lacks good quality clinical trials including an adequate comparative drug.
  2. DDD defined daily dose.
  3. Information provided in the reports of the Navarre Drug Assessment Working Group [Available in:].